non-holder here doing some DD: anyone has thoughts on the Ph 2 efficacy data for proteinuria comparing to the CSL Vifor data for sparsentan? DMX200 looks inferior to me and if sparsentan had issues meeting the primary endpoint in a Ph 3 why would DMX200 succeed?
Ann: Dimerix Presents at ASX Small & Mid-Cap Conference, page-41
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.040(9.76%) |
Mkt cap ! $247.7M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 45.5¢ | 41.5¢ | $585.0K | 1.333M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2461 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 230527 | 11 |
View Market Depth
| Last trade - 14.01pm 30/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |